Skip to content

FOXO4-DRI

Research Use Only
peptideInjection

Longevity peptide that selectively triggers senescent 'zombie cells' to self-destruct while sparing healthy cells. One of the most precise senolytic tools available.

Key Facts

  • Classification
    FOXO4-DRI is a D-retro-inverso peptide disrupting the FOXO4-p53 interaction in senescent cells, releasing p53 to trigger selective apoptosis while sparing healthy cells.
  • Primary Benefits
    Longevity (9/10) · Inflammation (6/10) · Skin & Hair (4/10)
  • Administration
    Injection
  • Typical Dose
    Dosing in humans is not well-established -- animal studies used ~5 mg/kg. Community protocols typically use much lower absolute doses. This is an experimental compound; start conservatively and consult a practitioner. Rest for 2 months between cycles.
  • Evidence Strength
    Emerging — 17 peer-reviewed studies referenced · Community sentiment 8/10
  • Stacks Well With
    Epithalon, GHK-Cu
  • Legal Status
    Research Use Only · not prescribable in US

Quick Facts

From price
$90
Type
peptide
Administration
Injection
Evidence
emerging
Studies referenced
17
Community sentiment
8/10
Stacks with
2 peptides
Regulatory
Research Use Only

Top benefits

⏳ Longevity
9/10
🧊 Inflammation
6/10
✨ Skin & Hair
4/10
View PricingCompare
1

Week 1–2

Effects are at cellular level — senescent cell clearance beginning. No immediate subjective changes expected. Possible mild flu-like symptoms from apoptotic cell debris. Note: zero human data exists for FOXO4-DRI.

2

Week 3–6

Senescent cell clearance continuing. Possible subtle improvements in tissue quality and energy as senescent cell burden decreases. Note: no human data exists — all expected effects are extrapolated from animal studies.

3

Week 8+

Cumulative senolytic benefits — improved tissue function, reduced inflammatory burden from senescent cells. Anti-aging effects observable.

Common Side Effects

Injection site reactionsFlu-like symptomsFatigueTransient inflammationVery limited human data
Tolerance: None — senolytic mechanism is event-based, not receptor-dependent
Cycling: 3-day intensive courses, spaced 2-4 weeks apart. Not for continuous use. Very experimental.

Scientific Overview

FOXO4-DRI is a D-retro-inverso peptide disrupting the FOXO4-p53 interaction in senescent cells, releasing p53 to trigger selective apoptosis while sparing healthy cells. Demonstrated restoration of fur density, renal function, and fitness in aged mice.

Dosing

Dosing in humans is not well-established -- animal studies used ~5 mg/kg. Community protocols typically use much lower absolute doses. This is an experimental compound; start conservatively and consult a practitioner. Rest for 2 months between cycles.

Reconstitution, storage, injection sites & timing

Benefit Profile

⏳ Longevity
9/10
🧊 Inflammation
6/10
✨ Skin & Hair
4/10
Medical oversight strongly recommendedNot safe during pregnancy· 4 contraindications